| 前收盘价格 | 4.27 |
| 收盘价格 | 4.30 |
| 成交量 | 598,027 |
| 平均成交量 (3个月) | 1,882,343 |
| 市值 | 533,681,856 |
| 价格/销量 (P/S) | 25.39 |
| 股市价格/股市净资产 (P/B) | 2.42 |
| 52周波幅 | |
| 利润日期 | 12 Nov 2025 |
| 稀释每股收益 (EPS TTM) | -0.550 |
| 总债务/股东权益 (D/E MRQ) | 1.86% |
| 流动比率 (MRQ) | 22.35 |
| 营业现金流 (OCF TTM) | -52.67 M |
| 杠杆自由现金流 (LFCF TTM) | -68.15 M |
| 资产报酬率 (ROA TTM) | -11.05% |
| 股东权益报酬率 (ROE TTM) | -19.70% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | I-MAB | 混合的 | 看涨 |
AIStockmoo 评分
0.0
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.0 |
| 平均 | 0.00 |
|
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 10.80% |
| 机构持股比例 | 29.64% |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合